Pharma ads, biotech IPOs, $1M longevity programs, oh my!

This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.

We cover:

Why pharma ads are surging and the growing push for restrictions on D2C drug advertising
Hims & Hers’ $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugs
The return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discovery
Vaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter funding
TrumpRx’s “most favored nation” drug pricing approach, and what one STAT analysis found
Bryan Johnson’s $1M per year “Immortals” longevity program

—

Show notes:

Should drug companies be advertising to consumers? (The New York Times)
Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)
Vaccine Makers Curtail Research and Cut Jobs (The New York Times)
TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)
Bryan Johnson's Immortals: $1M to try longevity regimen (Axios)

—

"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she’s written a book on how she went about it." - The WSJ

Massively Better Healthcare is out now!

—

Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here.

—

📍 Connect with us:

Heart of Healthcare website

LinkedIn

Instagram

Youtube

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.